SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow All Versions of this Article:
1470320309342735v1
10/3/147    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Redon, J.
Right arrow Articles by Fabia, M. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Redon, J.
Right arrow Articles by Fabia, M. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan

Josep Redon

Hypertension Clinic, Hospital Clínico Universitario, University of Valencia, Valencia, Spain, josep.redon{at}uv.es, CIBER 03/06 Physiopathology of Obesity and Nutrition, Institute of Health Carlos , Minister of Health, Spain

Maria Jose Fabia

Hypertension Clinic, Hospital Clínico Universitario, University of Valencia, Valencia, Spain, CIBER 03/06 Physiopathology of Obesity and Nutrition, Institute of Health Carlos , Minister of Health, Spain

A range of angiotensin II receptor blockers (ARB) is available, and analyses suggest there are differences between agents in terms of antihypertensive efficacy and 24-hour blood pressure control.This review assesses the data comparing olmesartan with other ARBs in terms of blood pressure reductions, goal achievement, 24-hour control and speed of onset. Olmesartan seems to have a more favourable efficacy profile relative to standard doses of the ARBs used in comparative studies; results consistent with the high degree of blockade of the angiotensin II type 1 receptor for olmesartan.Taken together, there might be differences between ARBs regarding their blood pressure lowering efficacy, and these results may provide further support of the benefits of olmesartan therapy since choice of an effective agent is crucial in antihypertensive therapy.

Key Words: angiotensin receptor blocker • blood pressure • hypertension • olmesartan • renin-angiotensin-aldosterone system

This version was published on September 1, 2009

Journal of Renin-Angiotensin-Aldosterone System, Vol. 10, No. 3, 147-156 (2009)
DOI: 10.1177/1470320309342735
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement